Big Pharma joins forces on $1B fund to shore up struggling antibiotics makers Harbour BioMed nabs meaty C round as cancer, COVID-19 work draws investors Blackstone hits $4.6B fundraising goal, teeing up big bets on late-phase R&D Sponsored: Keep post-pandemic trials on track: how the right clinical supply chain partner helps sponsors avoid trial disruption, now and going forward Oragenics cans lead program, a treatment for chemo, radiation side effects Cardurion nabs Takeda plasma therapy R&D chief as new CMO Oxford researchers develop portable COVID-19 test costing less than $25 Boehringer Ingelheim-backed COVID researchers identify new antibodies to fight the virus FiercePharmaAsia—Boehringer's Shanghai R&D hub; COVID-19 lessons from China; Botox trade secret war Chutes & Ladders—Cardurion taps Takeda veteran Morabito as chief medical officer Featured Story | By Amirah Al Idrus A who’s who of Big Pharma companies, including Pfizer, Johnson & Johnson and Merck, has banded together to bolster the development of new antibiotics. The companies announced Thursday the $1 billion AMR Action Fund, which aims to see two to four new antibiotics through approval by 2030. read more |
| |
|---|
|
Top Stories By Ben Adams Just a few months after a series B-plus worth $75 million, U.S.-China biotech Harbour BioMed has nabbed a major $102.8 million series C, with an IPO surely not far behind. read more By Nick Paul Taylor Blackstone Life Sciences has hit the target for its latest fund, giving it $4.6 billion to place a series of big bets. The vehicle, which Blackstone claims is the largest life sciences private fund, has already committed close to $1 billion to companies including Alnylam and Reata Pharmaceuticals. read more Monday, July 6, 2020 Facing a new reality, pharma and biotech companies must address ongoing clinical trial distribution challenges. Here's how a supply chain partner can help keep your post-pandemic clinical program on track. read more By Amirah Al Idrus Oragenics is bidding adieu to its lead program, a treatment designed to ward off inflammatory side effects from cancer treatments like chemotherapy and radiation. It’s halting a phase 2 study of the drug and yanking its Investigational New Drug application. The company will pivot its resources to developing a COVID-19 vaccine. read more By Ben Adams Since Takeda bought out Shire, it’s lost a number of high-ranking research execs from the Irish rare disease biotech, but today it’s also losing one from its own ranks. read more By Conor Hale The University of Oxford and its research center in China are launching a new company to develop a rapid COVID-19 test that could cost no more than £20, or about $25 U.S. read more By Arlene Weintraub By studying the antibody response to COVID-19 in 12 patients and immune cells from 48 healthy people, German researchers uncovered 28 antibodies that neutralize the virus. They're now working with Boehringer Ingelheim to advance the drugs into clinical testing. read more By Angus Liu Boehringer Ingelheim opened a new Shanghai site focused on external collaborations. Industry veterans talk about the ways COVID-19 is shifting pharma to digital. Evolus and South Korea's Daewoong face a 10-year Jeuveau ban in the U.S. as their Botox trade secrets brawl against Allergan proceeds. And more. read more By Kyle Blankenship Cardurion Pharma hires Takeda vet Morabito as CMO; Notable taps Wagner as first CSO; Kronos names Nicholson to head regulatory affairs. read more Resources Sponsored by: Salesforce Over the next five years, healthcare data is projected to grow at a rate of 36%. Innovations in drug therapy and technology have opened up new ways of capturing and analyzing information related to patient goals, priorities. Sponsored by: Cytiva On-demand video: fuel gene therapy development and production with modern AAV workflows. Sponsored by: LexisNexis Risk Solutions With today’s rapidly evolving environment, we have created this five-part content series to highlight pressing issues and topics that are more pertinent today than ever before. Sponsored by: Cambrex The industry trend of outsourcing to CDMOs continues. With more services, capabilities, facilities, and employees than ever before, our experts have contributed more articles to our biggest eBook yet. Sponsored by: EVERSANA How predictive analytics and machine learning have the potential to transform healthcare by predicting “Patient Switching Behaviors.” Sponsored by: Recro Gainesville Wurster processing is a versatile technique for developing and manufacturing multiparticulates for modified release dosage forms. Read this whitepaper to determine whether Wurster processing is the right option for your project. Sponsored by: PRA Health Sciences Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need. Sponsored by: Systech Get an inside look… Merck shares its next-generation approach to supply chain protection with new digital platforms, including Blockchain. Sponsored by: Automation Anywhere Built on advances in Artificial Intelligence (AI), data mining, and information integration into various systems at 100% accuracy, the new era of intelligent automation is integral to life sciences for devising new treatments faster and at a lower expense. Sponsored by: Research Solutions Learn four ways to squeeze more value from your limited R&D resources. Sponsored by: BioAnalytix Download this eBook and Learn the Advanced Analytical Approaches for Improved Development of Cell and Gene Therapies Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 